454 related articles for article (PubMed ID: 31752081)
1. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
Wojciechowska A; Osowski A; Jóźwik M; Górecki R; Rynkiewicz A; Wojtkiewicz J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752081
[TBL] [Abstract][Full Text] [Related]
2. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
3. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
[No Abstract] [Full Text] [Related]
4. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
5. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
6. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
7. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
[TBL] [Abstract][Full Text] [Related]
8. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
9. Inositols in PCOS.
Kamenov Z; Gateva A
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260918
[TBL] [Abstract][Full Text] [Related]
10. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS.
Facchinetti F; Bizzarri M; Benvenga S; D'Anna R; Lanzone A; Soulage C; Di Renzo GC; Hod M; Cavalli P; Chiu TT; Kamenov ZA; Bevilacqua A; Carlomagno G; Gerli S; Oliva MM; Devroey P
Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():72-76. PubMed ID: 26479434
[TBL] [Abstract][Full Text] [Related]
11. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
12. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
Gateva A; Unfer V; Kamenov Z
Gynecol Endocrinol; 2018 Jul; 34(7):545-550. PubMed ID: 29309199
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
14. Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Bizzarri M; Carlomagno G
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1896-903. PubMed ID: 25010620
[TBL] [Abstract][Full Text] [Related]
15. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Galazis N; Galazi M; Atiomo W
Gynecol Endocrinol; 2011 Apr; 27(4):256-62. PubMed ID: 21142777
[TBL] [Abstract][Full Text] [Related]
16. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
Colazingari S; Treglia M; Najjar R; Bevilacqua A
Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
[TBL] [Abstract][Full Text] [Related]
17. Inositols: From Established Knowledge to Novel Approaches.
Dinicola S; Unfer V; Facchinetti F; Soulage CO; Greene ND; Bizzarri M; Laganà AS; Chan SY; Bevilacqua A; Pkhaladze L; Benvenga S; Stringaro A; Barbaro D; Appetecchia M; Aragona C; Bezerra Espinola MS; Cantelmi T; Cavalli P; Chiu TT; Copp AJ; D'Anna R; Dewailly D; Di Lorenzo C; Diamanti-Kandarakis E; Hernández Marín I; Hod M; Kamenov Z; Kandaraki E; Monastra G; Montanino Oliva M; Nestler JE; Nordio M; Ozay AC; Papalou O; Porcaro G; Prapas N; Roseff S; Vazquez-Levin M; Vucenik I; Wdowiak A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638926
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.
Gerli S; Papaleo E; Ferrari A; Di Renzo GC
Eur Rev Med Pharmacol Sci; 2007; 11(5):347-54. PubMed ID: 18074942
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study.
Troisi J; Cinque C; Giugliano L; Symes S; Richards S; Adair D; Cavallo P; Sarno L; Scala G; Caiazza M; Guida M
J Ovarian Res; 2019 Mar; 12(1):25. PubMed ID: 30904021
[TBL] [Abstract][Full Text] [Related]
20. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
